Submit an Article
Navigate
Home
Editorial Board
Editorial Policies
Current Volume
Archive
Scientific Integrity
Publication Ethics Statements
Interviews with Outstanding Authors
Newsroom
Sponsored Conferences
Podcast
Contact
Special Collections
Submit an Article
Online ISSN: 1945-4589
Research Paper
|
Volume 12, Issue 11
|
pp. 10844–10862
Aberrantly glycosylated integrin α3β1 is a unique urinary biomarker for the diagnosis of bladder cancer
Back to article
Figure 1
(1 of 4)
−
100%
+
Figure 1.
Patient selection process and classification. Overall patient selection process and their classification based on types of diseases.
Figure 1 — Aberrantly glycosylated integrin α3β1 is a unique urinary biomarker for the diagnosis of bladder cancer | Aging
